ExpertiseUpdated on 26 April 2026
Services
About
Partex.AI is the world's largest AI-powered therapeutic asset accelerator, using Big Data, Generative AI, and proprietary models to optimize drug discovery and development from lab to patient.
Therapeutics
Focuses on identifying and de-risking late-stage preclinical/early clinical assets (especially oncology), incubating promising drugs in SPVs, and optimizing development paths with wet-lab validated AI predictions.
Exchange
Enables pharma/biotech partnerships for in/out-licensing deprioritized assets, using AI for evaluation, repositioning, and value-based deals across the pipeline.
Labs
Partex.AI Labs (Amgen spin-off in Regensburg) offers CRO services: custom assay development, cell line engineering, high-throughput screening (HTS with >150k library), bioactivity assessments, quantitative biology, and ADMETron™ for predictive ADMET/Tox from SMILES—delivering >300M data points and 95% success across targets like GPCRs and enzymes.
Data
Leverages Real-World Data (RWD) partnerships for equitable, patient-owned insights, enhancing clinical trials, treatment optimization, and decision-making via a centralized data lake.
Field
- Biotech, Pharma and Cosmetics
- Healthcare
Similar opportunities
Expertise
Oxeltis _ Bridge the gap between biology and chemical matter...
- Biotech, Pharma and Cosmetics
Christophe Parsy
Business & Strategic Development Director at Oxeltis
Montpellier, France
Expertise
Computational Biology Consultant | Biomarker Strategist | Pharma R&D, Data & AI
Amrita Roy Choudhury
Computational Biology Consultant | Biomarker Strategy | Pharma R&D, AI & Biological Data Analysis at BioInsight Advisory
Regensdorf, Switzerland
Partnership
Strategic Partnership for AI-Powered Drug Discovery & Design
Yanwu Guo
Investigator at ModelMole ltd
Oslo, Norway